



Publication of the 2015 Reference Document

Paris, Nantes, June 9, 2016 – OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), an immunotherapy company developing innovative treatments aiming at activating or regulating the immune system to restore immune disorders in immuno-oncology, autoimmune diseases and transplantation, today announced the publication of the company's 2015 Reference Document.

The company's 2015 Reference Document was filed with the French Market Authorities (Autorité des Marchés Financiers, AMF) on June 8, 2016 and registered under the number R.16-052. It is available on the AMF website: <http://www.amf-france.org> and on the company's website: <http://ose-immuno.com/en/>, section « Investors ».

This 2015 Reference Document includes the 2015 Annual Financial Report.

This document is also available upon mail request to the company's head office: Faculté de Médecine, 1 rue Gaston Veil, 44000 Nantes.

Risk factors

OSE Immunotherapeutics emphasizes the risks related to the company's business and described chapter 4: « Risk factors » of the 2015 Reference Document.

ABOUT OSE Immunotherapeutics

OSE Immunotherapeutics is a biotechnology company specializing in immune regulation with clinical applications in immuno-oncology, autoimmune diseases and transplantation. The company has a balanced portfolio, from R&D to clinical phase 3 registration, with a diversified risk profile. It is composed of advanced immunotherapy products in clinical phases 2 and 3, promising products in preclinical phase and potential drug candidates in R&D, targeting new receptors of interest in immuno-oncology, autoimmune and inflammatory diseases and transplantation. This product portfolio is supported by an innovative technology foundation and know-how in selection and optimization of new generation products acting on new immunological targets, notably, new generation check-point inhibitors.

Contacts

OSE Immunotherapeutics

Dominique Costantini, CEO
dominique.costantini@ose-immuno.com
Mob +33 6 13 20 77 49

Maryvonne Hiance, Vice Chairman
maryvonne.hiance@ose-immuno.com
Tél : +33 (0) 240 412 834
Mobile : 33 (0) 680 060 183

Alexis Peyroles, COO, Operations,
Finance & BD
alexis.peyroles@ose-immuno.com
Mob : +33 6 11 51 19 77

Bernard Vanhove, COO, R&D & Scientific
collaborations
bernard.vanhove@ose-immuno.com
Mob: +33 6 75 41 40 08

Contacts media

Citigate Dewe Rogerson
Laurence Bault
laurence.bault@citigate.fr
+33 1 53 32 84 78

Alize RP

Florence Portejoie & Caroline Carmagnol
oseimmuno@alizerp.com
+33 6 47 38 90 04

Consilium Strategic Communications

Chris Gardner / Matthew Neal /
Hendrik Thys
OSEImmuno@consilium-comms.com
+44 (0) 20 3709 5700

Rx Communications Group, LLC

Melody Carey
mcarey@rxir.com
+ 1 917-322-2571

Acorelis

Gilles Petitot
Mobile : 33 (0) 620 27 65 94
gilles.petitot@acorelis.com

Disclaimer

This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutic's management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.

These forward-looking statements include statements typically using conditional and containing verbs such as "expect", "anticipate", "believe", "target", "plan", or "estimate", their declensions and conjugations and words of similar import.

Although the OSE Immunotherapeutic's management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutic's shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance.

This press release includes only summary information and should be read with the OSE Immunotherapeutics Reference Document filed with the AMF on 8 June 2016 under the number R.15-052, the consolidated financial statements and the management report for the fiscal year 2015, as well as the Merger Document registered with the AMF on 26 April 2016 under number E.16-026, all available on the OSE Immunotherapeutic's website.

Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.